DOXIRIO-CV 325

Composition:

• Cefpodoxime Proxetil: 200mg

• Potassium Clavulanate: 125mg

Form: Tablet

Packaging: 10×10 Alu-Alu

Doxirio-CV 325 is a broad-spectrum antibiotic combining Cefpodoxime Proxetil, a third-generation cephalosporin, with Potassium Clavulanate, a beta-lactamase inhibitor.

Manufactured by Strio Healthcare under strict WHO-GMP quality standards.

This combination enhances antibacterial effectiveness and helps overcome resistance caused by beta-lactamase-producing bacteria.

Doxirio-CV 325 is widely prescribed for moderate to severe bacterial infections affecting multiple body systems.

Doxirio-CV 325 is used in the treatment of:

• Respiratory tract infections (bronchitis, pneumonia)

• Ear, nose, and throat infections (sinusitis, tonsillitis, otitis media)

• Urinary tract infections

• Skin and soft tissue infections

• Dental and post-surgical infections

Effective against infections caused by resistant bacterial strains.

Enhanced Antibacterial Coverage: The combination of Cefpodoxime and Clavulanate provides broad-spectrum activity.

Prevents Antibiotic Resistance: Potassium Clavulanate protects Cefpodoxime from enzymatic degradation.

High Patient Compliance: Alu-Alu blister packing ensures better stability and longer shelf life.

Faster Clinical Recovery: Helps reduce infection severity and duration when taken as prescribed.

Dosage:

• Usually 1 tablet twice daily, or as directed by a healthcare professional.

Administration:

• Swallow the tablet whole with water.

• Preferably take after food to reduce gastric discomfort.

• Do not skip doses and complete the full course of therapy.

Cefpodoxime Proxetil inhibits bacterial cell wall synthesis, leading to bacterial death.

Potassium Clavulanate inhibits beta-lactamase enzymes produced by resistant bacteria, allowing Cefpodoxime to act effectively.

Together, they provide strong, reliable antibacterial action against a wide range of pathogens.